- Home
- NKLR vs XFOR Comparison
NKLR vs XFOR Comparison
Compare NKLR & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKLR
- XFOR
- Stock Information
- Founded
- NKLR 2018
- XFOR 2014
- Country
- NKLR Italy
- XFOR United States
- Employees
- NKLR N/A
- XFOR N/A
- Industry
- NKLR Metal Fabrications
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NKLR Industrials
- XFOR Health Care
- Exchange
- NKLR Nasdaq
- XFOR Nasdaq
- Market Cap
- NKLR 398.3M
- XFOR 320.0M
- IPO Year
- NKLR N/A
- XFOR N/A
- Fundamental
- Price
- NKLR $4.47
- XFOR $3.68
- Analyst Decision
- NKLR
- XFOR Strong Buy
- Analyst Count
- NKLR 0
- XFOR 3
- Target Price
- NKLR N/A
- XFOR $34.67
- AVG Volume (30 Days)
- NKLR 1.8M
- XFOR 1.7M
- Earning Date
- NKLR 01-01-0001
- XFOR 11-05-2025
- Dividend Yield
- NKLR N/A
- XFOR N/A
- EPS Growth
- NKLR N/A
- XFOR N/A
- EPS
- NKLR N/A
- XFOR N/A
- Revenue
- NKLR N/A
- XFOR $33,979,000.00
- Revenue This Year
- NKLR N/A
- XFOR $1,307.51
- Revenue Next Year
- NKLR N/A
- XFOR N/A
- P/E Ratio
- NKLR N/A
- XFOR N/A
- Revenue Growth
- NKLR N/A
- XFOR 2925.74
- 52 Week Low
- NKLR $4.31
- XFOR $1.35
- 52 Week High
- NKLR $21.91
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- NKLR N/A
- XFOR 52.15
- Support Level
- NKLR N/A
- XFOR $3.49
- Resistance Level
- NKLR N/A
- XFOR $3.89
- Average True Range (ATR)
- NKLR 0.00
- XFOR 0.25
- MACD
- NKLR 0.00
- XFOR -0.02
- Stochastic Oscillator
- NKLR 0.00
- XFOR 44.94
About NKLR Terra Innovatum Global N.V. Ordinary shares
Terra Innovatum Global NV is a micro modular nuclear solutions company that aims to deliver reliable, low-cost and zero-carbon power wherever energy demand is present through its first-of-a-kind reactor SOLO. SOLO is compact yet extremely powerful with one unit generating 1MWe of power, while designed with the strictest safety characteristics and the ability to run 24/7 without the need to refuel for 15 years. Its modular design aims to achieve maximum energy efficiency while significantly reducing the levelized cost of energy (LCOE). SOLO is built using off-the-shelf components and widely available fuel, low-enriched uranium (LEU), which de-risks its regulatory and commercial pathway.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.